Medicenna Therapeutics Corp. (TSX: MDNA)
Health Care · Biotechnology · CA
CA$0.45
+3.45% today · -53.1% 1Y
Medicenna Therapeutics Corp. (TSX: MDNA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.36M and employs 15 people.
Over the last twelve months the share price has lost 53.1%, trading between 0.34 and 1.97.
Tweenvest scores Medicenna Therapeutics Corp. across four factors: quality 34/100, value 27/100. Its strongest factor is quality.
MDNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.36M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 2.10
- 52-week high
- CA$1.97
- 52-week low
- CA$0.34
- Avg volume (3M)
- —
- Shares outstanding
- 92.30M
- Employees
- 15
- Next earnings
- —
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent glioblastoma and is also being investigated for other brain and non-brain tumor types in earlier developmental stages. The company's pipeline also includes MDNA11, an improved IL-2 variant designed to stimulate immune responses against cancer; MDNA209, an IL-2 antagonist aimed at autoimmune conditions like multiple sclerosis and graft-versus-host disease; MDNA413, a dual IL-4/IL-13 antagonist for use in cancer immunotherapy; and MDNA132, an IL-13 Superkine targeting solid tumors. Furthermore, Medicenna utilizes its BiSKITs platform to engineer bespoke Superkines by joining them with proteins, antibodies, cytokines, or other Superkines. The company's main office is located in Toronto, Canada.
- ISIN
- CA58490H1073
- Listed since
- Mar 8, 2017
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Poltreg S.A.WSE: PTG | $29.79M | zł19.55 | +0.26% |
| Nicox S.A.ENXTPA: ALCOX | $29.74M | €0.30 | -2.91% |
| Cleo Diagnostics LtdASX: COV | $29.57M | AU$0.31 | -1.59% |
| Parataxis Korea, Inc.KOSDAQ: A288330 | $29.36M | ₩— | — |
| Quratis Inc.KOSDAQ: A348080 | $29.12M | ₩3,310.00 | -11.50% |
| Microbix Biosystems Inc.TSX: MBX | $29.05M | CA$0.30 | -3.23% |
| CEL-SCI CorporationNYSEAM: CVM | $28.85M | $1.64 | +1.86% |
| TransCode Therapeutics, Inc.NasdaqCM: RNAZ | $28.78M | $1.70 | -8.60% |
Figures last refreshed Oct 18, 2026.